Literature DB >> 12796707

The successful long-term treatment of age related erectile dysfunction with hSlo cDNA in rats in vivo.

A Melman1, W Zhao, K P Davies, R Bakal, G J Christ.   

Abstract

PURPOSE: We have previously reported that 1 intracorporeal injection of 100 microg hSlo/pcDNA reversed the effect of aging on erectile function in a rat model in vivo for at least 2 months. We report our further investigations of the amplitude, duration and physiological relevance of this novel gene transfer approach.
MATERIALS AND METHODS: A total of 191 retired breeder Sprague-Dawley rats were given a single intracavernous injection of phosphate buffered saline, 1,000 microg pcDNA, or 10, 100 or 1,000 microg pcDNA/hSlo. The animals were studied 1 to 6 months after injection. The intracorporeal pressure (ICP) response to cavernous nerve stimulation and immunostaining as well as hematoxylin and eosin staining were done to evaluate effector nerve integrity and tissue histology, respectively.
RESULTS: Gene transfer prevented an age related decrease in resting ICP and a physiologically relevant, significant effect on normalizing erection in vivo, as determined by submaximal (0.5 mA) and maximal (4.0 mA) cavernous nerve stimulation. The effects were observed 1 month after transfection and sustained for 6 months at the 100 and 1,000 microg doses of pcDNA/hSlo (p <0.026).
CONCLUSIONS: The physiological manifestations of gene transfer were detected as an amelioration of the age related decrease in resting ICP, and parallel increase in the magnitude of the cavernous nerve stimulated an ICP response to a level at which visible erections were again observed in this rat model of aging in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12796707     DOI: 10.1097/01.ju.0000063375.12512.6e

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  27 in total

Review 1.  Therapy of erectile dysfunction: potential future treatments.

Authors:  Nestor F Gonzalez-Cadavid; Jacob Rajfer
Journal:  Endocrine       Date:  2004 Mar-Apr       Impact factor: 3.633

Review 2.  Molecular mechanisms of detrusor and corporal myocyte contraction: identifying targets for pharmacotherapy of bladder and erectile dysfunction.

Authors:  George J Christ; Steve Hodges
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

3.  Vcsa1 acts as a marker of erectile function recovery after gene therapeutic and pharmacological interventions.

Authors:  Giulia Calenda; Yuehong Tong; Moses Tar; Daniel Lowe; Joseph Siragusa; Arnold Melman; Kelvin P Davies
Journal:  J Urol       Date:  2009-04-17       Impact factor: 7.450

4.  Variable coding sequence protein A1 as a marker for erectile dysfunction.

Authors:  Yuehong Tong; Moses Tar; Felix Davelman; George Christ; Arnold Melman; Kelvin P Davies
Journal:  BJU Int       Date:  2006-08       Impact factor: 5.588

5.  Sialorphin (the mature peptide product of Vcsa1) relaxes corporal smooth muscle tissue and increases erectile function in the ageing rat.

Authors:  Kelvin P Davies; Moses Tar; Catherine Rougeot; Arnold Melman
Journal:  BJU Int       Date:  2006-10-09       Impact factor: 5.588

Review 6.  Emerging and novel therapeutic approaches in the treatment of male erectile dysfunction.

Authors:  Eric Chung; Gerald B Brock
Journal:  Curr Urol Rep       Date:  2011-12       Impact factor: 3.092

Review 7.  Emerging tools for erectile dysfunction: a role for regenerative medicine.

Authors:  Lukman Hakim; Frank Van der Aa; Trinity J Bivalacqua; Petter Hedlund; Maarten Albersen
Journal:  Nat Rev Urol       Date:  2012-07-24       Impact factor: 14.432

8.  Ca2+ -activated K+ channel (KCa) stimulation improves relaxant capacity of PDE5 inhibitors in human penile arteries and recovers the reduced efficacy of PDE5 inhibition in diabetic erectile dysfunction.

Authors:  R González-Corrochano; Jm La Fuente; P Cuevas; A Fernández; Mx Chen; I Sáenz de Tejada; J Angulo
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

9.  Ageing causes cytoplasmic retention of MaxiK channels in rat corporal smooth muscle cells.

Authors:  K P Davies; Y Stanevsky; M T Tar; T Moses; J S Chang; M R Chance; A Melman
Journal:  Int J Impot Res       Date:  2007-02-08       Impact factor: 2.896

10.  Nanoparticles as a novel delivery vehicle for therapeutics targeting erectile dysfunction.

Authors:  George Han; Moses Tar; Dwaraka S R Kuppam; Adam Friedman; Arnold Melman; Joel Friedman; Kelvin P Davies
Journal:  J Sex Med       Date:  2009-09-18       Impact factor: 3.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.